Newsroom

Sorted by: Latest

-

Sensorion publie les données à six mois de l’essai clinique de Phase 1/2 Audiogene pour SENS-501 et poursuit le développement clinique du GJB2-GT (SENS-601) vers une première administration chez l’homme

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), Société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, publie aujourd’hui les données d’efficacité à six mois de la Cohorte 2 de l’essai clinique de Phase 1/2 Audiogene évaluant le SENS-501, sa thérapie génique pour le traitement de la surdité congénitale liée à des mutations du gè...
-

Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-in-Human Clinical Development

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported updated six-month efficacy data from Cohort 2 of the Audiogene Phase 1/2 clinical trial evaluating SENS-501, its gene therapy for the treatment of otoferlin-mediated congenital deafness, and provided a timeline update on the advancement of i...
-

Zluri Expands Platform to Deliver Identity Security for the Modern Enterprise

MILPITAS, Calif.--(BUSINESS WIRE)--Zluri today expanded its platform to deliver the Zluri Identity Security Platform, to monitor identities across the modern identity ecosystem....
-

SEMCO Technologies annonce le transfert de son contrat de liquidité auprès de Portzamparc (Groupe BNP Paribas)

CASTRIES, France--(BUSINESS WIRE)--Regulatory News :  SEMCO Technologies (Code ISIN : FR0014010H01 ; Mnémonique : ALSEM), entreprise spécialisée dans la conception et la fabrication de composants stratégiques pour la production de semi-conducteurs, annonce aujourd’hui avoir confié à Portzamparc (Groupe BNP Paribas), à compter du 23 mars 2026, et pour une durée d'un an renouvelable par tacite reconduction, la mise en œuvre d’un contrat de liquidité portant sur ses actions ordinaires. Ce contrat...
-

Eurofins: Convening Notice of the Shareholders to the Annual Ordinary General Meeting and an Extraordinary General Meeting of the Company Valid as an Information Notice for the Bondholders

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Disclaimer: this document is a non-binding English translation of the convening notice of the shareholders to the Annual Ordinary General Meeting and an Extraordinary General Meeting to be held on Thursday 23 April 2026 – the French version of the convening notice (“avis de convocation des actionnaires à l’assemblée générale ordinaire annuelle et une assemblée générale extraordinaire de la Société valant avis d’information des...
-

EUROFINS : AVIS DE CONVOCATION DES ACTIONNAIRES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE ET A UNE ASSEMBLEE GENERALE EXTRAORDINAIRE DE EUROFINS SCIENTIFIC SE (LA « SOCIETE ») VALANT AVIS D’INFORMATION DES OBLIGATAIRES

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) : EUROFINS SCIENTIFIC SE Société Européenne Siège social : 23, Val Fleuri, L-1526 Luxembourg Registre de Commerce et des Sociétés Luxembourg B167775 Les actionnaires de la Société, et uniquement avec voix consultative les porteurs de Deeply Subordinated Fixed to Floating Rate Bonds (ISIN: XS2579480307 et XS3038659267) et/ou de Senior Unsecured Euro Bonds (ISIN: XS2167595672, XS2491664137, XS2676883114, XS2343114687, et XS3135157...
-

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S....
-

FPT Recognized in Everest Group Application Development Services for AI Applications PEAK Matrix® Assessment 2025

HANOI, Vietnam--(BUSINESS WIRE)--Global IT services provider FPT has been positioned as a Major Contender in the Everest Group Application Development Services for AI Applications PEAK Matrix® Assessment 2025. The assessment evaluates 35 application development service providers on their ability to build and scale AI-powered enterprise applications, with emphasis on innovation, ecosystem partnerships, and AI talent readiness. The recognition reflects FPT’s end-to-end AI capabilities, spanning s...
-

Sysdig Celebrates 10 Years of Falco with $70,000 Donation

AMSTERDAM--(BUSINESS WIRE)--KubeCon + CloudNativeCon Europe 2026 – Sysdig, the leader in real-time AI-powered cloud defense, today announced a $70,000 donation to the Falco project through the Linux Foundation’s crowdfunding initiative. The donation comes as Falco celebrates its 10th anniversary this year, and on the heels of a Cloud Native Computing Foundation (CNCF) survey reporting that 82% of AI workloads are now built on Kubernetes, up from 54% just one year earlier. Sysdig’s contribution...
-

Indian Motorcycle Ranked Highest in 2026 Web Lead Response Study; Industry Enters 5th Year of Stagnant Performance

AUSTIN, Texas--(BUSINESS WIRE)--Indian Motorcycle dealerships ranked highest in 2026 web lead response study; industry wide - brands are leaving significant opportunity on the table...